eligibility_summary
Inclusion: Advanced solid tumors (escalation: NPC/SCLC, expansion: NPC/SCLC/NSCLC/other), ≥1 extracranial measurable lesion, tumor tissue available, adequate organs/marrow, ECOG 0-1, contraception, survival ≥3 months. Exclusion: local radical candidates, prior B7-H3, topo I/ADC, or immune checkpoint/cell therapy, recent major surgery/trauma or transplant, active autoimmune disease or systemic steroids, CNS mets, HIV/HBV/HCV, pregnancy/breastfeeding, severe allergy, other serious conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1 (China) testing YL201 plus serplulimab with or without platinum chemotherapy in advanced solid tumors. YL201: antibody-drug conjugate (ADC) targeting B7-H3 (CD276) on tumor cells, upon internalization, releases a topoisomerase I inhibitor payload to cause DNA damage and tumor cell death. Serplulimab: anti-PD-1 monoclonal antibody that blocks PD-1 on T cells to restore antitumor immunity. Platinum agents: cytotoxic chemotherapy that creates DNA crosslinks and can induce immunogenic cell death. Targets/pathways: B7-H3+ tumor cells, topo I/DNA replication, PD-1 checkpoint on T cells, DNA integrity via platinum.